Although the inhibitory effect of SSG on Il-1β, Ifn-γ, and Cxcl10 was weaker than that of canakinumab, SSG more effectively promoted the release of anti-inflammatory factors compared to classic treatments of gout (Supplementary Figure S1A). This evidence concerns the gene IL1B and gout.